HRP20120676T1 - Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije - Google Patents

Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije Download PDF

Info

Publication number
HRP20120676T1
HRP20120676T1 HRP20120676TT HRP20120676T HRP20120676T1 HR P20120676 T1 HRP20120676 T1 HR P20120676T1 HR P20120676T T HRP20120676T T HR P20120676TT HR P20120676 T HRP20120676 T HR P20120676T HR P20120676 T1 HRP20120676 T1 HR P20120676T1
Authority
HR
Croatia
Prior art keywords
thiomyosin
treatment
ptx3
gancyclovir
alone
Prior art date
Application number
HRP20120676TT
Other languages
English (en)
Croatian (hr)
Inventor
Romani Luigina
Bistoni Francesco
Garaci Enrico
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HRP20120676T1 publication Critical patent/HRP20120676T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20120676TT 2006-05-02 2007-04-12 Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije HRP20120676T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113401 2006-05-02
PCT/EP2007/053574 WO2007128647A1 (en) 2006-05-02 2007-04-12 USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

Publications (1)

Publication Number Publication Date
HRP20120676T1 true HRP20120676T1 (hr) 2012-09-30

Family

ID=36658736

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120676TT HRP20120676T1 (hr) 2006-05-02 2007-04-12 Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije

Country Status (18)

Country Link
US (1) US8337828B2 (https=)
EP (1) EP2012816B1 (https=)
JP (1) JP5441685B2 (https=)
KR (1) KR101380360B1 (https=)
CN (1) CN101437535B (https=)
AU (1) AU2007247292B2 (https=)
BR (1) BRPI0711136A2 (https=)
CA (1) CA2649063C (https=)
CY (1) CY1113277T1 (https=)
DK (1) DK2012816T3 (https=)
ES (1) ES2389452T3 (https=)
HR (1) HRP20120676T1 (https=)
MX (1) MX2008013872A (https=)
PL (1) PL2012816T3 (https=)
PT (1) PT2012816E (https=)
RS (1) RS52377B (https=)
SI (1) SI2012816T1 (https=)
WO (1) WO2007128647A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106868A (en) * 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
TW224053B (https=) * 1991-09-13 1994-05-21 Paul B Chretien
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6288033B1 (en) * 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20040198655A1 (en) 2001-08-03 2004-10-07 Alberto Mantovani Use of long pentraxin ptx3 for treating female infertility
WO2003035111A1 (en) * 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
JP2006524704A (ja) * 2003-04-23 2006-11-02 サイクローン・ファーマシューティカルズ・インコーポレイテッド アルファチモシンペプチドによる呼吸器ウイルス感染の治療または予防
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases

Also Published As

Publication number Publication date
CN101437535A (zh) 2009-05-20
KR20090007621A (ko) 2009-01-19
BRPI0711136A2 (pt) 2011-08-30
PT2012816E (pt) 2012-08-17
CA2649063C (en) 2014-11-25
CN101437535B (zh) 2013-01-30
RS52377B (sr) 2012-12-31
JP2009535373A (ja) 2009-10-01
DK2012816T3 (da) 2012-09-03
AU2007247292B2 (en) 2012-04-05
ES2389452T3 (es) 2012-10-26
JP5441685B2 (ja) 2014-03-12
US8337828B2 (en) 2012-12-25
CA2649063A1 (en) 2007-11-15
SI2012816T1 (sl) 2012-09-28
CY1113277T1 (el) 2016-04-13
AU2007247292A1 (en) 2007-11-15
MX2008013872A (es) 2008-11-14
WO2007128647A1 (en) 2007-11-15
HK1128622A1 (en) 2009-11-06
PL2012816T3 (pl) 2012-11-30
KR101380360B1 (ko) 2014-04-09
US20090275508A1 (en) 2009-11-05
EP2012816B1 (en) 2012-06-27
EP2012816A1 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
HRP20120676T1 (hr) Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije
CL2011000742A1 (es) Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.
PH12015500773B1 (en) Methods and compositions for live attenuated viruses
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
WO2009060429A3 (en) Compositions for conferring tolerance to viral disease in social insects, and the use thereof
HRP20241701T1 (hr) Modificirani nukleozidi, nukleotidi i nukleinske kiseline i njihova uporaba
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
WO2009025743A3 (en) Use of trail compositions as antiviral agents
WO2008045120A3 (en) Transgenic mouse lines expressing human ace2 and uses thereof
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
MX2010001849A (es) Depsipeptidos ciclicos.
EP2199391A4 (en) LATEN INFECTION TO HERPESVIRUS INVOLVED FACTOR AND USE THEREOF
BRPI0921424A2 (pt) vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
BRPI0922701A8 (pt) Método para intensificar atividade viral mediada por interferon em um animal de companhia
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
EP2489739A3 (en) Materials and methods for respiratory disease control in canines
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
Ma et al. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae
BR0310046A (pt) Atenuação de metapneumovìrus
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BRPI0600195A (pt) composição aquosa
DK1993585T3 (da) Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme